Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention

Charles L. Bennett, Charles J. Davidson, Dennis W. Raisch, Peter D. Weinberg, Richard H. Bennett, Marc D. Feldman

Research output: Contribution to journalArticlepeer-review

114 Scopus citations

Abstract

Background: One of the most unusual causes of thrombotic thrombocytopenic purpura (TTP), a life-threatening disease, is ticlopidine hydrochloride, an antiplatelet agent used to prevent strokes in high-risk populations or following coronary artery stent placement. Recently, Hoffman- LaRoche Pharmaceuticals, following reports of 20 deaths from ticlopidine- associated TTP, updated the information about the hematologic adverse effects of the drug. Objectives: To review our recent findings on ticlopidine- associated hematologic toxic effects, which served as the impetus for the revised warnings, and to discuss the implications of these findings. Methods: Data were obtained from the Food and Drug Administration's MedWatch program, published phase 3 clinical trials and case reports, hematologists, and plasmapheresis centers. Results: No cases of TTP have been reported in phase 3 ticlopidine trials. In contrast, postmarketing surveillance has identified serious adverse drug reactions to ticlopidine, resulting in 259 deaths, with TTP accounting for 40 of these deaths. Detailed information was available on 98 cases of ticlopidine-associated TTP. Compared with 42 patients in the coronary artery stent setting, 56 patients with ticlopidine-associated TTP in the stroke prevention setting were more likely to be women (62.5% vs 28.6%; P = .01). Before the onset of TTP in patients receiving stroke prevention therapy and patients with stent placement, ticlopidine had been used for less than 2 weeks in 5.4% and 2.4%, between 2 and 3 weeks in 17.9% and 21.4%, between 3 and 4 weeks in 30.4% and 38.1%, and between 4 and 12 weeks in 46.4% and 38.1%, respectively. Death occurred in almost 60% of all patients not receiving plasmapheresis compared with 21.9% of patients receiving plasmapheresis for stroke prevention and 14.3% of patients receiving plasmapheresis in the stent setting. Conclusions: Use of ticlopidine requires frequent physician visits and laboratory tests for at least 3 months in the stroke prevention setting, while, with short-term use in the coronary artery stent setting, adverse events are less likely to occur. These factors, as well as competition from clopidogrel bisulfate, a new antiplatelet agent, potentially limit the feasibility of ticlopidine as a stroke prevention agent, while having less impact on its use following coronary artery stent placement.

Original languageEnglish (US)
Pages (from-to)2524-2528
Number of pages5
JournalArchives of Internal Medicine
Volume159
Issue number21
DOIs
StatePublished - Nov 22 1999

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention'. Together they form a unique fingerprint.

Cite this